newsfilter
← Latest News
GlobeNewswire·

Aptose Reports Results for the Second Quarter 2023

─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67% in Patients with